文献速递主动脉疾病

胸主动脉腔内修复术治疗动脉瘤或急性主动脉综合征患者的中期结局差异:来自全球主动脉腔内治疗登记报告

Differences in Mid-Term Outcomes Between Patients Undergoing Thoracic Endovascular Aortic Repair for Aneurysm or Acute Aortic Syndromes: Report From the Global Registry for Endovascular Aortic Treatment.
PubMed 文献 · J Endovasc Ther · 2021-12-15

基于全球主动脉腔内治疗登记(GREAT),分析575例接受胸主动脉腔内修复术(TEVAR)患者,其中降胸主动脉瘤(DTAA)305例、急性主动脉综合征(AAS)270例。30天全因死亡率DTAA为1.3%、AAS为1.8%(p=0.741),1年及3年死亡率、主动脉相关死亡率及再干预率组间均无显著差异;AAS患者1年内主动脉相关死亡更常见,TEVAR后仅1年时再干预率更高。

要点

  • DTAA与AAS患者TEVAR后30天全因死亡率分别为1.3%与1.8%(p=0.741)。
  • 1年及3年全因死亡率DTAA为6.2%与17.3%,AAS为9.3%与15.9%(p=0.209与p=0.655)。
  • AAS患者1年内主动脉相关死亡更常见,TEVAR后仅1年时再干预率更高。

核心结论

  • 接受TEVAR的DTAA或AAS患者在中远期随访各年份间死亡率和再干预率存在差异。
  • 30天内全因死亡与TEVAR相关,而AAS患者1年内主动脉相关死亡更常见。
  • AAS患者再干预率更高,但仅出现在TEVAR后1年时。

研究设计与样本

  • 基于全球主动脉腔内治疗登记(GREAT)的分析,纳入因AAS或DTAA接受TEVAR的患者。
  • 共分析575例患者,其中DTAA 305例、AAS 270例。
  • 主要结局为30天全因死亡率;次要结局为30天主动脉相关死亡率和再干预率,以及1年和3年全因死亡率、主动脉相关死亡率和再干预率。
  • 另将随访分为3个时段(1-30天、31-365天、366-1096天)进行专项分析,描述两组间差异及每组内的时间趋势。

主要发现

  • 30天死亡率DTAA为1.3%、AAS为1.8%(p=0.741)。
  • 1年和3年死亡率DTAA为6.2%和17.3%,AAS为9.3%和15.9%(p=0.209和p=0.655)。
  • 30天、1年和3年主动脉相关死亡率DTAA为1.3%、1.3%和2.6%,AAS为1.8%、4.2%和4.2%(p=ns)。
  • 30天、1年和3年再干预率DTAA为1.3%、4.3%和7.5%,AAS为3.3%、8.1%和10.7%(p=ns)。

关键数值与推荐

  • 30天全因死亡率DTAA 1.3% vs AAS 1.8%(p=0.741)。
  • 1年全因死亡率DTAA 6.2% vs AAS 9.3%(p=0.209);3年全因死亡率DTAA 17.3% vs AAS 15.9%(p=0.655)。
  • 30天、1年、3年主动脉相关死亡率DTAA 1.3%、1.3%、2.6% vs AAS 1.8%、4.2%、4.2%(p=ns)。
  • 30天、1年、3年再干预率DTAA 1.3%、4.3%、7.5% vs AAS 3.3%、8.1%、10.7%(p=ns)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze differences in baseline characteristics, overall mortality, device-related mortality, and re-intervention rates in patients who underwent thoracic endovascular aortic repair (TEVAR) for descending thoracic aortic aneurysm (DTAA) with atherosclerotic/degenerative cause or acute aortic syndrome (AAS), using the Global Registry For Endovascular Aortic Treatment (GREAT). MATERIALS AND METHODS: Patients submitted to TEVAR for AAS or DTAA, included in GREAT, were eligible for this analysis. Primary outcome was 30-day all-cause mortality rate. Secondary outcomes were 30-day aorta-related mortality and re-intervention rate, 1-year and 3-year all-cause mortality, aorta-related mortality and re-intervention rate. RESULTS: Five-hundred and seventy-five patients were analyzed (305 DTAA and 270 AAS). Thirty-day mortality rate was 1.3% and 1.8% for DTAA and AAS, respectively (p=0.741). One-year and 3-year mortality rates were 6.2% versus 9.3 and 17.3% versus 15.9% for DTAA and AAS, respectively (p=0.209 and p=0.655, respectively). Aorta-related mortality rates at 30 days, 1 year and 3 years were 1.3%, 1.3%, and 2.6% for DTAA, 1.8%, 4.2%, and 4.2% for AAS (p=ns). Re-intervention rates at 30 days, 1 year, and 3 years were 1.3%, 4.3%, and 7.5% for DTAA, 3.3%, 8.1%, and 10.7% for AAS (p=ns). Furthermore, a specific analysis with similar outcomes was performed dividing follow-up in 3 periods (1-30 days, 31-365 days, 366-1096 days) and describing mutual differences between 2 groups and temporal trends in each group. CONCLUSION: Patients who underwent TEVAR for DTAA or AAS experienced different mortality and re-intervention rates among years during mid-term follow-up. Although all-cause related deaths within 30 days were TEVAR-related, aorta-related deaths were more common for AAS patients within 1 year. A greater re-intervention rate was described for AAS patients, although only 1 year after TEVAR.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Bissacco D, Domanin M, Weaver FA, et al. Differences in Mid-Term Outcomes Between Patients Undergoing Thoracic Endovascular Aortic Repair for Aneurysm or Acute Aortic Syndromes: Report From the Global Registry for Endovascular Aortic Treatment. J Endovasc Ther. 2021. PMID: 34911391. doi:10.1177/15266028211064819

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。